In the BioHarmony Drug Report Database
Besifloxacin
Besivance (besifloxacin) is a small molecule pharmaceutical. Besifloxacin was first approved as Besivance on 2009-05-28. It is used to treat bacterial conjunctivitis, bacterial infections, and protozoan infections in the USA. Besivance’s patents are valid until 2031-01-09 (FDA).
Trade Name
|
Besivance |
|---|---|
Common Name
|
besifloxacin |
ChEMBL ID
|
CHEMBL1201760 |
Indication
|
bacterial conjunctivitis, bacterial infections, protozoan infections |
Drug Class
|
Antibacterials (quinolone derivatives) |
Image (chem structure or protein)